Therapeutic agent

Montelukast Tablets Oral Treatment

PreliminaryEvidence level
1Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Leukotriene antagonist (10mg daily) for MCAS/inflammatory overlap. Supported by MCAS obs + urticaria RCTs. Low-risk add-on.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT06597682Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEctionNot applicableNot yet recruiting

Key Studies / References

  • See linked studies